ORPHAGEN PHARMACEUTICALS, INC.

Orphagen Pharmaceuticals, Inc. is a San Diego-based preclinical-stage biopharmaceutical company pioneering first-in-class small molecule therapies targeting orphan nuclear receptors — a validated drug target class that has produced major treatments across inflammation, oncology, and metabolic disease. Founded by Scott Thacher, Ph.D., a Harvard-trained biophysicist with over 30 years of pharmaceutical R&D experience including leadership roles at Allergan (now AbbVie), Orphagen focuses on blocking unexplored members of the nuclear receptor superfamily to address cancers and autoimmune diseases with high unmet medical need. The company's most advanced programs include OR-449, a first-in-class clinical candidate targeting the orphan nuclear receptor SF-1 (NR5A1) for adrenocortical cancer (ACC), a rare adrenal gland malignancy; and OR-812, a differentiated oral small molecule therapy for ulcerative colitis, Crohn's disease, and other gut inflammatory conditions. Orphagen has secured 20+ NIH/SBIR and other grants over its history, partnering with leading academic centers and attracting an experienced scientific advisory board committed to translational drug discovery and development.